Cryptyx Bioscience

Cryptyx Bioscience is a Princeton-based biopharmaceutical platform company that is opening new doors to drug discovery by tapping into hidden therapeutics in nature. Cryptyx utilizes the simplest and fastest natural product drug discovery platform aimed at activating silent biosynthetic gene clusters in bacteria and at unlocking the full potential of any culturable microbe. Cryptyx's technology is the only genetics-free, cloning-free, bioactivity-first platform for accessing ‘hidden’ therapeutic natural products encoded in bacteria. Using a broadly applicable, high-throughput, genetics-free, and cloning-free approach, Cryptyx provides the simplest and fastest natural product drug discovery platform which can rapidly activate silent biosynthetic genes in bacteria, unlocking the full potential of any culturable microbe. Cryptyx Bioscience aims to combat infectious disease by tackling CDC and NIAID priority agents. Three out of 5 programs are under development for CDC threats: Clostridium difficile, Neisseria gonorrhoeae, and Mycobacterium tuberculosis (TB). Other programs include Respiratory syncytial virus (RSV) and Melioidosis.